Whole-organism high-throughput screening against Trypanosoma brucei brucei

Bibliography

• Simarro PP, Cecchi G, Franco JR, Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis 2012;6(10):e1859
   PubMed Web of Science ®Google Scholar
• Simarro PP, Diarra A, Ruiz Postigo JA, The human African trypanosomiasis control and surveillance programme of the world health organization 2000–2009: the way forward. PLoS Negl Trop Dis 2011;5(2):e1007
   PubMed Web of Science ®Google Scholar
• Hoare CA, Mulligan HW. The mammalian trypanosomes of Africa, in the african trypanosomiases. George Allen and Unwin LTD, London; 1970. p. 3-23
   Google Scholar
• Pepin J, Meda HA. The epidemiology and control of human African trypanosomiasis. Adv Parasitol 2001;49:71-132
   PubMed Web of Science ®Google Scholar
• Vickerman K. Developmental cycles and biology of pathogenic trypanosomes. Br Med Bull 1985;41(2):105-14
   PubMed Web of Science ®Google Scholar
• Apted FIC, Mulligan HW. Clinical manifestations and diagnosis of sleeping sickness, in the African trypanosomiases. George Allen and Unwin LTD, London; 1970. p. 661-83
   Google Scholar
• Atouguia JM, Kennedy PGE, Davis LE, Neurological aspects of human African trypanosomiasis in infectious diseases of the nervous system. Butterworth-Heinemann, Oxford; 2000. p. 321-72
   Google Scholar
• Gelfand M. Transitory neurological signs in sleeping sickness. Trans R Soc Trop Med Hyg 1947;41(2):255-8
   PubMed Web of Science ®Google Scholar
• Lundkvist GB, Kristensson K, Bentivoglio M. Why trypanosomes cause sleeping sickness. Physiology 2004;19(4):198-206
   PubMedGoogle Scholar
• Bentivoglio M, Grassi-Zucconi G, Olsson T, Trypanosoma brucei and the nervous system. Trends Neurosci 1994;17(8):325-9
   PubMed Web of Science ®Google Scholar
• Apted FIC, Mullerhorvath R. Treatment of human trypanosomiasis, in the African trypanosomiases. George Allen and Unwin Ltd, London; 1970. p. 684-725
   Google Scholar
• Burri C, Stich A, Brun R, Current Chemotherapy of human African trypanosomiasis, in the trypanosomiases. CABI Publishing, Trowbridge; 2004. p. 403-19
   Google Scholar
• World Health Organisation. Control and surveillance of African trypanosomiasis. World Health Organization, Geneve; 1998
   Google Scholar
• Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994;33:1-47
   PubMed Web of Science ®Google Scholar
• Blum J, Burri C. Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Med Wkly 2002;132(5-6):51-6
   PubMed Web of Science ®Google Scholar
• Bacchi CJ, Nathan HC, Hutner SH. Polyamine metabolism - a potential therapeutic target in trypanosomes. Science 1980;210(4467):332-4
   PubMed Web of Science ®Google Scholar
• Takigawa M, Verma AK, Simsiman RC, Polyamine biosynthesis and skin tumor promotion: inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin tumor formation by the irreversible inhibitor of ornithine decarboxylase alpha-difluoromethylornithine. Biochem Biophys Res Commun 1982;105(3):969-76
   PubMed Web of Science ®Google Scholar
• Chappuis F, Udayraj N, Stietenroth K, Eflornithine is safer than melarsoprol for the treatment of second stage trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005;41(5):748-51
   PubMed Web of Science ®Google Scholar
• Priotto G, Pinoges L, Fursa IB, Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008;336(7646):705-8
   PubMed Web of Science ®Google Scholar
• Milford EPJ. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping. Lancet 1992;340(8820):652
   PubMed Web of Science ®Google Scholar
• Chappuis F. Melarsoprol-free drug combinations for second-stage gambian sleeping sickness: the way to go. Clin Infect Dis 2007;45(11):1443-5
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Mutombo W, Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009;374(9683):56-64
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Ngouama D, Nifurtimox-eflornithine combination therapy for second-stage trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in congo. Clin Infect Dis 2007;45(11):1435-42
   PubMed Web of Science ®Google Scholar
• Simarro PP, Jannin J, Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 2008;5(2):e55
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Resolution 50.36, 50th world health assembly. World Health Organisation, Geneva; 1997
   Google Scholar
• Hawking F. Drug-resistance of trypanosoma congolense and other trypanosomes to quinapyramine, phenanthridines, berenil and other compounds in mice. Ann Trop Med Parasitol 1963;57:262-82
   PubMed Web of Science ®Google Scholar
• Kaminsky R, Gumm ID, Zweygarth E, A drug incubation infectivity test (DIIT) for assessing resistance in trypanosomes. Vet Parasitol 1990;34(4):335-43
   PubMed Web of Science ®Google Scholar
• Hirumi H, Hirumi K. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol 1989;75(6):985-9
   PubMed Web of Science ®Google Scholar
• Baltz T, Baltz D, Giroud C, Cultivation in a semi-defined medium of animal infective forms of trypanosoma brucei, trypanosoma equiperdum, trypanosoma evansi, Trypanosoma rhodesiense and T gambiense. EMBO J 1985;4(5):1273-7
   PubMed Web of Science ®Google Scholar
• Duszenko M, Ferguson MA, Lamont GS, Cysteine eliminates the feeder cell requirement for cultivation of Trypanosoma brucei bloodstream forms in vitro. J Exp Med 1985;162(4):1256-63
   PubMed Web of Science ®Google Scholar
• Borowy NK, Hirumi H, Waithaka HK, An assay for screening drugs against animal-infective bloodstream forms of Trypanosoma brucei brucei in vitro. Drugs Exp Clin Res 1985;11(3):155-61
   PubMedGoogle Scholar
• Sykes ML, Avery VM. Development of an Alamar blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am J Trop Med Hyg 2009;81(4):665-74
   PubMed Web of Science ®Google Scholar
• Lanteri CA, Stewart ML, Brock JM, Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance. Mol Pharmacol 2006;70(5):1585-92
   PubMed Web of Science ®Google Scholar
• Merschjohann K, Steverding D. In vitro growth inhibition of bloodstream forms of Trypanosoma brucei and Trypanosoma congolense by iron chelators. Kinetoplastid Biol Dis 2006;5:3
   PubMedGoogle Scholar
• Kaminsky R, Zweygarth E. Feeder layer-free in vitro assay for screening antitrypanosomal compounds against Trypanosoma brucei brucei and T. b. evansi. Antimicrob Agents Chemother 1989;33(6):881-5
   PubMed Web of Science ®Google Scholar
• Brun R, Kunz C. In vitro drug sensitivity test for Trypanosoma brucei subgroup bloodstream trypomastigotes. Acta Trop 1989;46(5–6):361-8
   PubMed Web of Science ®Google Scholar
• Ali JA, Creek DJ, Burgess K, Pyrimidine salvage in trypanosoma brucei bloodstream forms and the trypanocidal action of halogenated pyrimidines. Mol Pharmacol 2013;83(2):439-53
   PubMed Web of Science ®Google Scholar
• Hammond DJ, Gutteridge WE. Purine and pyrimidine metabolism in the Trypanosomatidae. Mol Biochem Parasitol 1984;13(3):243-61
   PubMed Web of Science ®Google Scholar
• Hammond DJ, Gutteridge WE. UMP synthesis in the kinetoplastida. Biochim Biophys Acta 1982;718(1):1-10
   PubMed Web of Science ®Google Scholar
• Zinsstag J, Brun R, Gessler M. A new photometric assay for testing trypanocidal activity in vitro. Parasitol Res 1991;77(1):33-8
   PubMed Web of Science ®Google Scholar
• Grant PT, Fulton JD. The catabolism of glucose by strains of Trypanosoma rhodesiense. Biochem J 1957;66(2):242-50
   PubMed Web of Science ®Google Scholar
• Bodley AL, McGarry MW, Shapiro TA. Drug cytotoxicity assay for african trypanosomes and leishmania species. J Infect Dis 1995;172(4):1157-9
   PubMed Web of Science ®Google Scholar
• Räz B, Iten M, Grether-Bühler Y, The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Tropica 1997;68(2):139-47
   PubMed Web of Science ®Google Scholar
• de Fries R, Mitsuhashi M. Quantification of mitogen induced human lymphocyte proliferation: comparison of alamarBlue assay to 3H-thymidine incorporation assay. J Clin Lab Anal 1995;9(2):89-95
   PubMed Web of Science ®Google Scholar
• Bienen EJ, Webster P, Fish WR. Trypanosoma (Nannomonas) congolense: changes in respiratory metabolism during the life cycle. Exp Parasitol 1991;73(4):403-12
   PubMed Web of Science ®Google Scholar
• Page B, Page M, Noel C. A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol 1993;3(3):473-6
   PubMed Web of Science ®Google Scholar
• Changtam C, de Koning HP, Ibrahim H, Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 2010;45(3):941-56
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4(2):67-73
   PubMed Web of Science ®Google Scholar
• Iversen PW, Eastwood BJ, Sittampalam GS, A comparison of assay performance measures in screening assays: signal window, ZÊ factor, and assay variability ratio. J Biomol Screen 2006;11(3):247-52
   PubMed Web of Science ®Google Scholar
• Sui Y, Wu Z. Alternative statistical parameter for high-throughput screening assay quality assessment. J Biomol Screen 2007;12(2):229-34
   PubMed Web of Science ®Google Scholar
• Mackey ZB, Baca AM, Mallari JP, Discovery of trypanocidal compounds by whole cell HTS of trypanosoma brucei. Chem Biol Drug Des 2006;67(5):355-63
   PubMed Web of Science ®Google Scholar
• DeLuca M, Dempsey ME. Mechanism of oxidation in firefly luminescence. Biochem Biophys Res Commun 1970;40(1):117-22
   PubMed Web of Science ®Google Scholar
• Sykes ML, Avery VM. A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Parasit Vectors 2009;2(1):54
   PubMedGoogle Scholar
• Gould MK, Vu XL, Seebeck T, Propidium iodide-based methods for monitoring drug action in the kinetoplastidae: comparison with the Alamar Blue assay. Anal Biochem 2008;382(2):87-93
   PubMed Web of Science ®Google Scholar
• Rodenko B, van der Burg AM, Wanner MJ, 2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities. Antimicrob Agents Chemother 2007;51(11):3796-802
   PubMed Web of Science ®Google Scholar
• De Rycker M, O'Neill S, Joshi D, A static-cidal assay for trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. PLoS Negl Trop Dis 2012;6(11):e1932
   PubMedGoogle Scholar
• Capes A, Patterson S, Wyllie S, Quinol derivatives as potential trypanocidal agents. Bioorg Medl Chem 2012;20(4):1607-15
   PubMed Web of Science ®Google Scholar
• Torreele E, Bourdin TB, Tweats D, Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 2010;4(12):e923
   PubMed Web of Science ®Google Scholar
• Smith VC, Cleghorn LAT, Woodland A, Optimisation of the anti-trypanosoma brucei activity of the opioid agonist U50488. ChemMedChem 2011;6(10):1832-40
   PubMed Web of Science ®Google Scholar
• Mercer L, Bowling T, Perales J, 2,4-Diaminopyrimidines as potent inhibitors of trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLoS Negl Trop Dis 2011;5(2):e956
   PubMedGoogle Scholar
• Jacobs RT, Nare B, Wring SA, SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011;5(6):e1151
   PubMed Web of Science ®Google Scholar
• Nare B, Wring S, Bacchi C, Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis. Antimicrob Agents Chemother 2010;54(10):4379-88
   PubMed Web of Science ®Google Scholar
• König J, Wyllie S, Wells G, Antitumor Quinol PMX464 Is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. J Biol Chem 2011;286(10):8523-33
   PubMed Web of Science ®Google Scholar
• Jones DC, Hallyburton I, Stojanovski L, Identification of a kappa-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol 2010;80(10):1478-86
   PubMed Web of Science ®Google Scholar
• Frearson JA, Brand S, McElroy SP, N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 2010;464(7289):728-32
   PubMed Web of Science ®Google Scholar
• Merschjohann K, Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide. Exp Parasitol 2008;118(4):637-40
   PubMed Web of Science ®Google Scholar
• Bodley AL, Wani MC, Wall ME, Antitrypanosomal activity of camptothecin analogs: structure-activity correlations. Biochem Pharmacol 1995;50(7):937-42
   PubMed Web of Science ®Google Scholar
• Sykes ML, Baell JB, Kaiser M, Identification of compounds with anti-proliferative activity against trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl Trop Dis 2012;6(11):e1896
   PubMedGoogle Scholar
• Navarro G, Chokpaiboon S, De Muylder G, Hit-to-Lead Development of the chamigrane endoperoxide merulin A for the treatment of African sleeping sickness. PLoS One 2012;7(9):e46172
   PubMedGoogle Scholar
• Johnson TA, Sohn J, Inman WD, Natural product libraries to accelerate the high-throughput discovery of therapeutic leads. J Nat Prod 2011;74(12):2545-55
   PubMed Web of Science ®Google Scholar
• Abiodun O, Gbotosho G, Ajaiyeoba E, Antitrypanosomal activity of some medicinal plants from Nigerian ethnomedicine. Parasitol Res 2012;110(2):521-6
   PubMed Web of Science ®Google Scholar
• Watts KR, Ratnam J, Ang K-H, Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi. Bioorg Med Chem 2010;18(7):2566-74
   PubMed Web of Science ®Google Scholar
• Orhan I, Sener B, Kaiser M, Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar Drugs 2010;8(1):47-58
   PubMed Web of Science ®Google Scholar
• dos Santos DA, de CBPA, da Silva MF, Anti-African trypanocidal and antimalarial activity of natural flavonoids, dibenzoylmethanes and synthetic analogues. J Pharm Pharmacol 2009;61(2):257-66
   PubMed Web of Science ®Google Scholar
• Feng Y, Davis RA, Sykes ML, Iotrochamides A and B, antitrypanosomal compounds from the Australian marine sponge Iotrochota sp. Bioorg Med Chem Lett 2012;22(14):4873-6
   PubMed Web of Science ®Google Scholar
• Davis RA, Sykes M, Avery VM, Convolutamines I and J, antitrypanosomal alkaloids from the bryozoan Amathia tortusa. Bioorg Med Chem 2011;19(22):6615-19
   PubMed Web of Science ®Google Scholar
• Davis RA, Demirkiran O, Sykes ML, 7',8'-Dihydroobolactone, a typanocidal alpha-pyrone from the rainforest tree Cryptocarya obovata. Bioorg Med Chem Lett 2010;20(14):4057-9
   PubMed Web of Science ®Google Scholar
• Feng YJ, Davis RA, Sykes M, Antitrypanosomal cyclic polyketide peroxides from the Australian marine sponge plakortis sp. J Nat Prod 2010;73(4):716-19
   PubMed Web of Science ®Google Scholar
• Feng YJ, Davis RA, Sykes ML, Antitrypanosomal pyridoacridine alkaloids from the Australian ascidian Polysyncraton echinatum. Tetrahedron Lett 2010;51(18):2477-9
   Web of Science ®Google Scholar
• Kaiser M, Bray MA, Cal M, Anti-trypanosomal activity of fexinidazole - a new oral nitroimidazole drug candidate for the treatment of sleeping sickness. Antimicrob Agents Chemother 2011;55(12):5602-8
   PubMed Web of Science ®Google Scholar
• Ding D, Zhao Y, Meng Q, Discovery of novel benzoxaborole-based potent antitrypanosomal agents. ACS Med Chem Lett 2010;1(4):165-9
   PubMed Web of Science ®Google Scholar
• Kuettel S, Mosimann M, Mäser P, Adenosine Kinase of T. b. rhodesiense identified as the putative target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine using chemical proteomics. PLoS Negl Trop Dis 2009;3(8):e506
   PubMedGoogle Scholar
• Vincent IM, Creek DJ, Burgess K, Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei. PLoS Negl Trop Dis 2012;6(5):e1618
   PubMed Web of Science ®Google Scholar
• Vincent IM, Creek D, Watson DG, A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 2010;6(11):e1001204
   PubMed Web of Science ®Google Scholar
• Luscher A, de Koning HP, Maser P. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting. Curr Pharm Des 2007;13(6):555-67
   PubMed Web of Science ®Google Scholar